PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Gross profit growth under 50% of CRVO's 100.00%. Michael Burry would be concerned about a severe competitive disadvantage.
56.85%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
54.90%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
56.85%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
56.86%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
56.86%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while CRVO is at 2.84%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while CRVO is at 2.84%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
28.81%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
28.81%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while CRVO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.99%
10Y OCF/share CAGR in line with CRVO's 99.86%. Walter Schloss would see both as similarly efficient over the decade.
56.40%
5Y OCF/share CAGR at 50-75% of CRVO's 83.95%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-114.69%
Negative 3Y OCF/share CAGR while CRVO stands at 75.32%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
96.39%
Similar net income/share CAGR to CRVO's 99.90%. Walter Schloss would see parallel tailwinds or expansions for both firms.
45.76%
5Y net income/share CAGR at 50-75% of CRVO's 84.49%. Martin Whitman might see a shortfall in operational efficiency or brand power.
32.63%
Below 50% of CRVO's 77.33%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-96.80%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-86.34%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-81.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.00%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-9.98%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-36.64%
Our R&D shrinks while CRVO invests at 5.59%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-70.64%
We cut SG&A while CRVO invests at 37.03%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.